Roxana Daneshjou, Eric R Gamazon, Ben Burkley, Larisa H Cavallari, Julie A Johnson, Teri E Klein, Nita Limdi, Sara Hillenmeyer, Bethany Percha, Konrad J Karczewski, Taimour Langaee, Shitalben R Patel, Carlos D Bustamante, Russ B Altman, Minoli A Perera. Blood 2014
Times Cited: 43
Times Cited: 43
Times Cited
Times Co-cited
Similarity
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
Minoli A Perera, Larisa H Cavallari, Nita A Limdi, Eric R Gamazon, Anuar Konkashbaev, Roxana Daneshjou, Anna Pluzhnikov, Dana C Crawford, Jelai Wang, Nianjun Liu,[...]. Lancet 2013
Minoli A Perera, Larisa H Cavallari, Nita A Limdi, Eric R Gamazon, Anuar Konkashbaev, Roxana Daneshjou, Anna Pluzhnikov, Dana C Crawford, Jelai Wang, Nianjun Liu,[...]. Lancet 2013
48
A pharmacogenetic versus a clinical algorithm for warfarin dosing.
Stephen E Kimmel, Benjamin French, Scott E Kasner, Julie A Johnson, Jeffrey L Anderson, Brian F Gage, Yves D Rosenberg, Charles S Eby, Rosemary A Madigan, Robert B McBane,[...]. N Engl J Med 2013
Stephen E Kimmel, Benjamin French, Scott E Kasner, Julie A Johnson, Jeffrey L Anderson, Brian F Gage, Yves D Rosenberg, Charles S Eby, Rosemary A Madigan, Robert B McBane,[...]. N Engl J Med 2013
44
Estimation of the warfarin dose with clinical and pharmacogenetic data.
T E Klein, R B Altman, N Eriksson, B F Gage, S E Kimmel, M-T M Lee, N A Limdi, D Page, D M Roden, M J Wagner,[...]. N Engl J Med 2009
T E Klein, R B Altman, N Eriksson, B F Gage, S E Kimmel, M-T M Lee, N A Limdi, D Page, D M Roden, M J Wagner,[...]. N Engl J Med 2009
44
A randomized trial of genotype-guided dosing of warfarin.
Munir Pirmohamed, Girvan Burnside, Niclas Eriksson, Andrea L Jorgensen, Cheng Hock Toh, Toby Nicholson, Patrick Kesteven, Christina Christersson, Bengt Wahlström, Christina Stafberg,[...]. N Engl J Med 2013
Munir Pirmohamed, Girvan Burnside, Niclas Eriksson, Andrea L Jorgensen, Cheng Hock Toh, Toby Nicholson, Patrick Kesteven, Christina Christersson, Bengt Wahlström, Christina Stafberg,[...]. N Engl J Med 2013
34
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
B F Gage, C Eby, J A Johnson, E Deych, M J Rieder, P M Ridker, P E Milligan, G Grice, P Lenzini, A E Rettie,[...]. Clin Pharmacol Ther 2008
B F Gage, C Eby, J A Johnson, E Deych, M J Rieder, P M Ridker, P E Milligan, G Grice, P Lenzini, A E Rettie,[...]. Clin Pharmacol Ther 2008
27
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
Nita A Limdi, Mia Wadelius, Larisa Cavallari, Niclas Eriksson, Dana C Crawford, Ming-Ta M Lee, Chien-Hsiun Chen, Alison Motsinger-Reif, Hersh Sagreiya, Nianjun Liu,[...]. Blood 2010
Nita A Limdi, Mia Wadelius, Larisa Cavallari, Niclas Eriksson, Dana C Crawford, Ming-Ta M Lee, Chien-Hsiun Chen, Alison Motsinger-Reif, Hersh Sagreiya, Nianjun Liu,[...]. Blood 2010
27
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
Mark J Rieder, Alexander P Reiner, Brian F Gage, Deborah A Nickerson, Charles S Eby, Howard L McLeod, David K Blough, Kenneth E Thummel, David L Veenstra, Allan E Rettie. N Engl J Med 2005
Mark J Rieder, Alexander P Reiner, Brian F Gage, Deborah A Nickerson, Charles S Eby, Howard L McLeod, David K Blough, Kenneth E Thummel, David L Veenstra, Allan E Rettie. N Engl J Med 2005
25
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
Fumihiko Takeuchi, Ralph McGinnis, Stephane Bourgeois, Chris Barnes, Niclas Eriksson, Nicole Soranzo, Pamela Whittaker, Venkatesh Ranganath, Vasudev Kumanduri, William McLaren,[...]. PLoS Genet 2009
Fumihiko Takeuchi, Ralph McGinnis, Stephane Bourgeois, Chris Barnes, Niclas Eriksson, Nicole Soranzo, Pamela Whittaker, Venkatesh Ranganath, Vasudev Kumanduri, William McLaren,[...]. PLoS Genet 2009
20
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.
Gregory M Cooper, Julie A Johnson, Taimour Y Langaee, Hua Feng, Ian B Stanaway, Ute I Schwarz, Marylyn D Ritchie, C Michael Stein, Dan M Roden, Joshua D Smith,[...]. Blood 2008
Gregory M Cooper, Julie A Johnson, Taimour Y Langaee, Hua Feng, Ian B Stanaway, Ute I Schwarz, Marylyn D Ritchie, C Michael Stein, Dan M Roden, Joshua D Smith,[...]. Blood 2008
18
CYP4F2 genetic variant alters required warfarin dose.
Michael D Caldwell, Tarif Awad, Julie A Johnson, Brian F Gage, Mat Falkowski, Paul Gardina, Jason Hubbard, Yaron Turpaz, Taimour Y Langaee, Charles Eby,[...]. Blood 2008
Michael D Caldwell, Tarif Awad, Julie A Johnson, Brian F Gage, Mat Falkowski, Paul Gardina, Jason Hubbard, Yaron Turpaz, Taimour Y Langaee, Charles Eby,[...]. Blood 2008
18
The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.
M A Perera, E Gamazon, L H Cavallari, S R Patel, S Poindexter, R A Kittles, D Nicolae, N J Cox. Clin Pharmacol Ther 2011
M A Perera, E Gamazon, L H Cavallari, S R Patel, S Poindexter, R A Kittles, D Nicolae, N J Cox. Clin Pharmacol Ther 2011
18
Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.
Larisa H Cavallari, Minoli Perera, Mia Wadelius, Panos Deloukas, Gelson Taube, Shitalben R Patel, Keston Aquino-Michaels, Marlos A G Viana, Nancy L Shapiro, Edith A Nutescu. Pharmacogenet Genomics 2012
Larisa H Cavallari, Minoli Perera, Mia Wadelius, Panos Deloukas, Gelson Taube, Shitalben R Patel, Keston Aquino-Michaels, Marlos A G Viana, Nancy L Shapiro, Edith A Nutescu. Pharmacogenet Genomics 2012
32
Genetic and clinical predictors of warfarin dose requirements in African Americans.
L H Cavallari, T Y Langaee, K M Momary, N L Shapiro, E A Nutescu, W A Coty, M A G Viana, S R Patel, J A Johnson. Clin Pharmacol Ther 2010
L H Cavallari, T Y Langaee, K M Momary, N L Shapiro, E A Nutescu, W A Coty, M A G Viana, S R Patel, J A Johnson. Clin Pharmacol Ther 2010
16
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.
Simone Rost, Andreas Fregin, Vytautas Ivaskevicius, Ernst Conzelmann, Konstanze Hörtnagel, Hans-Joachim Pelz, Knut Lappegard, Erhard Seifried, Inge Scharrer, Edward G D Tuddenham,[...]. Nature 2004
Simone Rost, Andreas Fregin, Vytautas Ivaskevicius, Ernst Conzelmann, Konstanze Hörtnagel, Hans-Joachim Pelz, Knut Lappegard, Erhard Seifried, Inge Scharrer, Edward G D Tuddenham,[...]. Nature 2004
16
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.
Katarzyna Drozda, Shan Wong, Shitalben R Patel, Adam P Bress, Edith A Nutescu, Rick A Kittles, Larisa H Cavallari. Pharmacogenet Genomics 2015
Katarzyna Drozda, Shan Wong, Shitalben R Patel, Adam P Bress, Edith A Nutescu, Rick A Kittles, Larisa H Cavallari. Pharmacogenet Genomics 2015
16
Race influences warfarin dose changes associated with genetic factors.
Nita A Limdi, Todd M Brown, Qi Yan, Jonathan L Thigpen, Aditi Shendre, Nianjun Liu, Charles E Hill, Donna K Arnett, T Mark Beasley. Blood 2015
Nita A Limdi, Todd M Brown, Qi Yan, Jonathan L Thigpen, Aditi Shendre, Nianjun Liu, Charles E Hill, Donna K Arnett, T Mark Beasley. Blood 2015
16
Pharmacogenomics knowledge for personalized medicine.
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein. Clin Pharmacol Ther 2012
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein. Clin Pharmacol Ther 2012
16
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
J A Johnson, K E Caudle, L Gong, M Whirl-Carrillo, C M Stein, S A Scott, M T Lee, B F Gage, S E Kimmel, M A Perera,[...]. Clin Pharmacol Ther 2017
J A Johnson, K E Caudle, L Gong, M Whirl-Carrillo, C M Stein, S A Scott, M T Lee, B F Gage, S E Kimmel, M A Perera,[...]. Clin Pharmacol Ther 2017
16
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
G P Aithal, C P Day, P J Kesteven, A K Daly. Lancet 1999
G P Aithal, C P Day, P J Kesteven, A K Daly. Lancet 1999
13
Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese.
Pei-Chieng Cha, Taisei Mushiroda, Atsushi Takahashi, Michiaki Kubo, Shiro Minami, Naoyuki Kamatani, Yusuke Nakamura. Hum Mol Genet 2010
Pei-Chieng Cha, Taisei Mushiroda, Atsushi Takahashi, Michiaki Kubo, Shiro Minami, Naoyuki Kamatani, Yusuke Nakamura. Hum Mol Genet 2010
13
Cytochrome p-450 polymorphisms and response to clopidogrel.
Jessica L Mega, Sandra L Close, Stephen D Wiviott, Lei Shen, Richard D Hockett, John T Brandt, Joseph R Walker, Elliott M Antman, William Macias, Eugene Braunwald,[...]. N Engl J Med 2009
Jessica L Mega, Sandra L Close, Stephen D Wiviott, Lei Shen, Richard D Hockett, John T Brandt, Joseph R Walker, Elliott M Antman, William Macias, Eugene Braunwald,[...]. N Engl J Med 2009
13
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Mitchell K Higashi, David L Veenstra, L Midori Kondo, Ann K Wittkowsky, Sengkeo L Srinouanprachanh, Fred M Farin, Allan E Rettie. JAMA 2002
Mitchell K Higashi, David L Veenstra, L Midori Kondo, Ann K Wittkowsky, Sengkeo L Srinouanprachanh, Fred M Farin, Allan E Rettie. JAMA 2002
13
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
Nita A Limdi, Donna K Arnett, Joyce A Goldstein, T Mark Beasley, Gerald McGwin, Brian K Adler, Ronald T Acton. Pharmacogenomics 2008
Nita A Limdi, Donna K Arnett, Joyce A Goldstein, T Mark Beasley, Gerald McGwin, Brian K Adler, Ronald T Acton. Pharmacogenomics 2008
13
Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans.
H Schelleman, J Chen, Z Chen, J Christie, C W Newcomb, C M Brensinger, M Price, A S Whitehead, C Kealey, C F Thorn,[...]. Clin Pharmacol Ther 2008
H Schelleman, J Chen, Z Chen, J Christie, C W Newcomb, C M Brensinger, M Price, A S Whitehead, C Kealey, C F Thorn,[...]. Clin Pharmacol Ther 2008
11
A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.
P J Avery, A Jorgensen, A K Hamberg, M Wadelius, M Pirmohamed, F Kamali. Clin Pharmacol Ther 2011
P J Avery, A Jorgensen, A K Hamberg, M Wadelius, M Pirmohamed, F Kamali. Clin Pharmacol Ther 2011
11
Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.
Y Liu, H Jeong, H Takahashi, K Drozda, S R Patel, N L Shapiro, E A Nutescu, L H Cavallari. Clin Pharmacol Ther 2012
Y Liu, H Jeong, H Takahashi, K Drozda, S R Patel, N L Shapiro, E A Nutescu, L H Cavallari. Clin Pharmacol Ther 2012
11
HLA-B*5701 screening for hypersensitivity to abacavir.
Simon Mallal, Elizabeth Phillips, Giampiero Carosi, Jean-Michel Molina, Cassy Workman, Janez Tomazic, Eva Jägel-Guedes, Sorin Rugina, Oleg Kozyrev, Juan Flores Cid,[...]. N Engl J Med 2008
Simon Mallal, Elizabeth Phillips, Giampiero Carosi, Jean-Michel Molina, Cassy Workman, Janez Tomazic, Eva Jägel-Guedes, Sorin Rugina, Oleg Kozyrev, Juan Flores Cid,[...]. N Engl J Med 2008
11
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
S A Scott, K Sangkuhl, C M Stein, J-S Hulot, J L Mega, D M Roden, T E Klein, M S Sabatine, J A Johnson, A R Shuldiner. Clin Pharmacol Ther 2013
S A Scott, K Sangkuhl, C M Stein, J-S Hulot, J L Mega, D M Roden, T E Klein, M S Sabatine, J A Johnson, A R Shuldiner. Clin Pharmacol Ther 2013
11
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Jessica L Mega, Tabassome Simon, Jean-Philippe Collet, Jeffrey L Anderson, Elliott M Antman, Kevin Bliden, Christopher P Cannon, Nicolas Danchin, Betti Giusti, Paul Gurbel,[...]. JAMA 2010
Jessica L Mega, Tabassome Simon, Jean-Philippe Collet, Jeffrey L Anderson, Elliott M Antman, Kevin Bliden, Christopher P Cannon, Nicolas Danchin, Betti Giusti, Paul Gurbel,[...]. JAMA 2010
11
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
J A Johnson, L Gong, M Whirl-Carrillo, B F Gage, S A Scott, C M Stein, J L Anderson, S E Kimmel, M T M Lee, M Pirmohamed,[...]. Clin Pharmacol Ther 2011
J A Johnson, L Gong, M Whirl-Carrillo, B F Gage, S A Scott, C M Stein, J L Anderson, S E Kimmel, M T M Lee, M Pirmohamed,[...]. Clin Pharmacol Ther 2011
11
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.
D Voora, D C Koboldt, C R King, P A Lenzini, C S Eby, R Porche-Sorbet, E Deych, M Crankshaw, P E Milligan, H L McLeod,[...]. Clin Pharmacol Ther 2010
D Voora, D C Koboldt, C R King, P A Lenzini, C S Eby, R Porche-Sorbet, E Deych, M Crankshaw, P E Milligan, H L McLeod,[...]. Clin Pharmacol Ther 2010
11
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.
Giovanna D'Andrea, Rosa Lucia D'Ambrosio, Pasquale Di Perna, Massimiliano Chetta, Rosa Santacroce, Vincenzo Brancaccio, Elvira Grandone, Maurizio Margaglione. Blood 2005
Giovanna D'Andrea, Rosa Lucia D'Ambrosio, Pasquale Di Perna, Massimiliano Chetta, Rosa Santacroce, Vincenzo Brancaccio, Elvira Grandone, Maurizio Margaglione. Blood 2005
9
Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.
Stuart A Scott, Rame Khasawneh, Inga Peter, Ruth Kornreich, Robert J Desnick. Pharmacogenomics 2010
Stuart A Scott, Rame Khasawneh, Inga Peter, Ruth Kornreich, Robert J Desnick. Pharmacogenomics 2010
9
Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing?
Stuart A Scott, Steven A Lubitz. Pharmacogenomics 2014
Stuart A Scott, Steven A Lubitz. Pharmacogenomics 2014
22
Pharmacogenetics of warfarin: current status and future challenges.
M Wadelius, M Pirmohamed. Pharmacogenomics J 2007
M Wadelius, M Pirmohamed. Pharmacogenomics J 2007
9
Integration of genetic, clinical, and INR data to refine warfarin dosing.
P Lenzini, M Wadelius, S Kimmel, J L Anderson, A L Jorgensen, M Pirmohamed, M D Caldwell, N Limdi, J K Burmester, M B Dowd,[...]. Clin Pharmacol Ther 2010
P Lenzini, M Wadelius, S Kimmel, J L Anderson, A L Jorgensen, M Pirmohamed, M D Caldwell, N Limdi, J K Burmester, M B Dowd,[...]. Clin Pharmacol Ther 2010
9
Genetic warfarin dosing: tables versus algorithms.
Brian S Finkelman, Brian F Gage, Julie A Johnson, Colleen M Brensinger, Stephen E Kimmel. J Am Coll Cardiol 2011
Brian S Finkelman, Brian F Gage, Julie A Johnson, Colleen M Brensinger, Stephen E Kimmel. J Am Coll Cardiol 2011
9
Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.
Elaine M Hylek, Carmella Evans-Molina, Carol Shea, Lori E Henault, Susan Regan. Circulation 2007
Elaine M Hylek, Carmella Evans-Molina, Carol Shea, Lori E Henault, Susan Regan. Circulation 2007
9
Warfarin pharmacogenetics: an illustration of the importance of studies in minority populations.
M A Perera, L H Cavallari, J A Johnson. Clin Pharmacol Ther 2014
M A Perera, L H Cavallari, J A Johnson. Clin Pharmacol Ther 2014
12
The largest prospective warfarin-treated cohort supports genetic forecasting.
Mia Wadelius, Leslie Y Chen, Jonatan D Lindh, Niclas Eriksson, Mohammed J R Ghori, Suzannah Bumpstead, Lennart Holm, Ralph McGinnis, Anders Rane, Panos Deloukas. Blood 2009
Mia Wadelius, Leslie Y Chen, Jonatan D Lindh, Niclas Eriksson, Mohammed J R Ghori, Suzannah Bumpstead, Lennart Holm, Ralph McGinnis, Anders Rane, Panos Deloukas. Blood 2009
9
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
S Mallal, D Nolan, C Witt, G Masel, A M Martin, C Moore, D Sayer, A Castley, C Mamotte, D Maxwell,[...]. Lancet 2002
S Mallal, D Nolan, C Witt, G Masel, A M Martin, C Moore, D Sayer, A Castley, C Mamotte, D Maxwell,[...]. Lancet 2002
9
SLCO1B1 variants and statin-induced myopathy--a genomewide study.
E Link, S Parish, J Armitage, L Bowman, S Heath, F Matsuda, I Gut, M Lathrop, R Collins. N Engl J Med 2008
E Link, S Parish, J Armitage, L Bowman, S Heath, F Matsuda, I Gut, M Lathrop, R Collins. N Engl J Med 2008
9
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.
Michael V Holmes, Pablo Perel, Tina Shah, Aroon D Hingorani, Juan P Casas. JAMA 2011
Michael V Holmes, Pablo Perel, Tina Shah, Aroon D Hingorani, Juan P Casas. JAMA 2011
9
Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans.
Adam Bress, Shitalben R Patel, Minoli A Perera, Richard T Campbell, Rick A Kittles, Larisa H Cavallari. Pharmacogenomics 2012
Adam Bress, Shitalben R Patel, Minoli A Perera, Richard T Campbell, Rick A Kittles, Larisa H Cavallari. Pharmacogenomics 2012
9
Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.
Andrea H Ramirez, Yaping Shi, Jonathan S Schildcrout, Jessica T Delaney, Hua Xu, Matthew T Oetjens, Rebecca L Zuvich, Melissa A Basford, Erica Bowton, Min Jiang,[...]. Pharmacogenomics 2012
Andrea H Ramirez, Yaping Shi, Jonathan S Schildcrout, Jessica T Delaney, Hua Xu, Matthew T Oetjens, Rebecca L Zuvich, Melissa A Basford, Erica Bowton, Min Jiang,[...]. Pharmacogenomics 2012
9
Pharmacogenomics of warfarin in populations of African descent.
Guilherme Suarez-Kurtz, Mariana R Botton. Br J Clin Pharmacol 2013
Guilherme Suarez-Kurtz, Mariana R Botton. Br J Clin Pharmacol 2013
13
Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans.
S E Kimmel, J Christie, C Kealey, Z Chen, M Price, C F Thorn, C M Brensinger, C W Newcomb, A S Whitehead. Pharmacogenomics J 2008
S E Kimmel, J Christie, C Kealey, Z Chen, M Price, C F Thorn, C M Brensinger, C W Newcomb, A S Whitehead. Pharmacogenomics J 2008
9
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Alan R Shuldiner, Jeffrey R O'Connell, Kevin P Bliden, Amish Gandhi, Kathleen Ryan, Richard B Horenstein, Coleen M Damcott, Ruth Pakyz, Udaya S Tantry, Quince Gibson,[...]. JAMA 2009
Alan R Shuldiner, Jeffrey R O'Connell, Kevin P Bliden, Amish Gandhi, Kathleen Ryan, Richard B Horenstein, Coleen M Damcott, Ruth Pakyz, Udaya S Tantry, Quince Gibson,[...]. JAMA 2009
9
Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Mary J Emond, Tin Louie, Julia Emerson, Wei Zhao, Rasika A Mathias, Michael R Knowles, Fred A Wright, Mark J Rieder, Holly K Tabor, Deborah A Nickerson,[...]. Nat Genet 2012
Mary J Emond, Tin Louie, Julia Emerson, Wei Zhao, Rasika A Mathias, Michael R Knowles, Fred A Wright, Mark J Rieder, Holly K Tabor, Deborah A Nickerson,[...]. Nat Genet 2012
9
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Shaun Purcell, Benjamin Neale, Kathe Todd-Brown, Lori Thomas, Manuel A R Ferreira, David Bender, Julian Maller, Pamela Sklar, Paul I W de Bakker, Mark J Daly,[...]. Am J Hum Genet 2007
Shaun Purcell, Benjamin Neale, Kathe Todd-Brown, Lori Thomas, Manuel A R Ferreira, David Bender, Julian Maller, Pamela Sklar, Paul I W de Bakker, Mark J Daly,[...]. Am J Hum Genet 2007
9
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.